Cathie Wood Gamida Cell Ltd. Transaction History

Ark Investment Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	SELL	$0.04 - $0.46 $85,717 - $985,751	-2,142,938 Reduced 99.93%	1,484 $0
Q4 2023 Jan 17, 2024	BUY	$0.25 - $1.02 $181,201 - $739,302	724,806 Added 51.06%	2,144,422 $879,000
Q3 2023 Oct 18, 2023	BUY	$0.85 - $1.87 $1.21 Million - $2.65 Million	1,419,616 New	1,419,616 $1.46 Million
Q2 2022 Jul 11, 2022	SELL	$1.73 - $4.29 $240,412 - $596,168	-138,967 Reduced 16.28%	714,534 $1.56 Million
Q1 2022 Apr 19, 2022	BUY	$2.22 - $4.47 $227,399 - $457,871	102,432 Added 13.64%	853,501 $3.54 Million
Q4 2021 Jan 28, 2022	BUY	$2.2 - $4.46 $280,269 - $568,181	127,395 Added 20.43%	751,069 $1.91 Million
Q3 2021 Nov 12, 2021	SELL	$3.85 - $6.44 $252,001 - $421,530	-65,455 Reduced 9.5%	623,674 $2.45 Million
Q2 2021 Aug 05, 2021	BUY	$5.85 - $8.33 $110,009 - $156,645	18,805 Added 2.81%	689,129 $4.42 Million
Q1 2021 May 13, 2021	BUY	$7.8 - $12.43 $2.72 Million - $4.33 Million	348,298 Added 108.16%	670,324 $5.42 Million
Q4 2020 Feb 12, 2021	BUY	$4.07 - $11.0 $551,936 - $1.49 Million	135,611 Added 72.75%	322,026 $2.7 Million
Q3 2020 Oct 30, 2020	BUY	$3.93 - $4.59 $732,610 - $855,644	186,415 New	186,415 $774,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.